AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22063371
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution 1mL.kg(‐1) as placebo
Trial: 19808137
Drug: Flurbiprofen 50-mg
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50-mg orally disintegrating tablet (ODT)
Trial: 19808137
Drug: Conventional flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional flurbiprofen 50-mg tablet
Trial: 9558411
Drug: IdCSA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdCSA (1 mg/kg/d from day -1 to +20; n = 28)
Trial: 9558411
Drug: IdCSA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdCSA + IdMTX (10 mg/m2 for day +1, 8 mg/m2 for days +3, +6, and +11; n = 32)
Trial: 9522741
Drug: 5 commonly
RxNorm normalized name: Common timothy
DrugBank: Phleum pratense top (DB14179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 commonly prescribed syrup medications
Trial: 2574566
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol hydrochloride
Trial: 1091822
Drug: Prazosin (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (3.0 to 7.5 mg per day)
Trial: 1091822
Drug: Methyldopa or
RxNorm normalized name: methyldopa Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa or Propranolol (given in comparable doses)
Trial: 25040636
Drug: Verbal education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal education based on an Australian National Prescribing Service patient leaflet regarding antibiotics
Trial: 21331636
Drug: G-Coat Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Coat Plus (GP)
Trial: 15111525
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet(12h))
Trial: 15111525
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet(morn+bed))
Trial: 15111525
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (pooled)
Trial: 9589700
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg daily) for 6 months
Trial: 8051377
Drug: Antibiotic prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylactic treatment including cephapirine, gentamicin and metronidazole
Trial: 2522716
Drug: Heparin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (titrated to partial thromboplastin time 1.5 to 2.5 times normal) administered for 18 to 24 hours
Trial: 2522716
Drug: Dextrose administered
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose administered for 18 to 24 hours
Trial: 28484316
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25 percent bupivacaine + 5 mg morphine (0.5 mL) infiltrated in Group P
Trial: 25271729
Drug: PK-guided individualized
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PK-guided individualized dosing of pazopanib
Trial: 25271729
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of pazopanib (800 mg once daily)
Trial: 18949545
Drug: Ruboxistaurin (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (32 mg/day for 6 weeks)
Trial: 9201803
Drug: Flumazenil (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (cumulative doses of 0.05, 0.10, 0.25, 0.50 and 1.00 mg at 15-min intervals)
Trial: 1283061
Drug: Titrated, oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated, oral, double-blind, placebo-controlled challenge (DBPCFC) with fresh egg or milk
Trial: 3516953
Drug: MFD (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFD (3 X 1.6 Gy/day for 10 days, 3 weeks rest, followed by a boost to 67.2 or 72 Gy) + Misonidazole (1 g/m2 every irradiation day, total 12 to 14 g/m2)
Trial: 26987980
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day oral diclofenac
Trial: 26987980
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg methylprednisolone injection
Trial: 26987980
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (diclofenac + methylprednisolone)
Trial: 17460970
Drug: Trimethasidine MB
RxNorm normalized name: Ionosol-MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethasidine MB (70 mg daily)
Trial: 17460970
Drug: 3‐TMHP (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐TMHP (1000 mg daily)
Trial: 17460970
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic therapy with ACE inhibitors, beta-blockers, and diuretics)
Trial: 9807986
Drug: Irinotecan 300-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 300-350 mg/m2 infused once every 3 weeks
Trial: 9807986
Drug: Fluorouracil by
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil by continuous infusion
Trial: 100029
Drug: Streptomycin, isoniazid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin, isoniazid, and rifampin given daily for 6 months
Trial: 100029
Drug: Streptomycin, isoniazid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin, isoniazid, rifampin, and pyrazinamide given daily for 2 months, followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Trial: 100029
Drug: Streptomycin, isoniazid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin, isoniazid, rifampin, and pyrazinamide given 3 times per week for 4 months, followed by streptomycin, isoniazid, and pyrazinamide administered twice per week
Trial: 26454228
Drug: Preconceptional micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconceptional micronutrient supplements
Trial: 23506690
Drug: Traditional herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional herbal medicine (THM) regimen including Cinobufacini injection and Jiedu Granule
Trial: 11815577
Drug: Clarithromycin MR
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin MR 500 mg once daily for 5 days
Trial: 11815577
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 590 mg three times daily for 10 days
Trial: 24367678
Drug: Efavirenz-based antiretroviral
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based antiretroviral therapy
Trial: 23381882
Drug: Ritonavir 20
RxNorm normalized name: ritonavir 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 20 mg (phase 2)
Trial: 23381882
Drug: Ritonavir 100
RxNorm normalized name: ritonavir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 100 mg (phase 3)
Trial: 17309962
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential pneumatic compression (ISPC) device activated over the lower limbs 15 minutes after PPP was established for the remainder of surgery.
Trial: 7978435
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms oral clonidine administered just before anesthesia
Trial: 7978435
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms oral clonidine administered 1 h before anesthesia
Trial: 7978435
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms oral clonidine administered 3 h before anesthesia
Trial: 1104900
Drug: standard hormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard hormonal or other therapies
Trial: 23406306
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling by phone, access to twice‐weekly exercise sessions, information on healthy eating and physical activity provided in pamphlets, evening meetings and an interactive website.
Trial: 21726928
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (Group AGO)
Trial: 21726928
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Group ANTAG)
Trial: 12851342
Drug: Hylan G‐F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G‐F 20 (Synvisc)
Trial: 10383511
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose spearmint (500 mg)
Trial: 10383511
Drug: Flavouring dose
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flavouring dose spearmint (0.5 mg)
Trial: 8723601
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone (2 mg/kg in 15 min followed by 1 mg/kg in 2 h)
Trial: 1685992
Drug: Urapidil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (40 mg bolus followed by an infusion of 18 mg.h‐1 for 2 h)
Trial: 6809393
Drug: Almitrine at
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine at a dose of 0.5 mg h‐1 kg‐1 given intravenously over 2 h
Trial: 25778317
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiotherapy combined with concurrent combination chemotherapy (cisplatin and 5‐fluorouracil)
Trial: 22390068
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei DN - 114001 (109 cells daily for 3 months)
Trial: 8097925
Drug: Epanolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol (200 mg)
Trial: 8097925
Drug: Epanolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol (mean 300 mg/day for 10 months)
Trial: 8097925
Drug: Epanolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol (300 mg/day)
Trial: 8097925
Drug: Atenolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (150 mg/day)
Trial: 22475362
Drug: Bleeding-avoidance strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleeding-avoidance strategies (BAS) including direct thrombin inhibitors and vascular closure devices
Trial: 19821701
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with an 830-nm diode laser, 40 mW, 1.04 J per point, applied on days 1, 3, 5, and 7 post-surgery
Trial: 15969244
Drug: Cimicifuga racemosa
RxNorm normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifuga racemosa (CR) 40 mg daily
Trial: 15969244
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal estradiol (TTSE2) 25 microg every 7 days plus dihydrogesterone 10 mg/day for the last 12 days
Trial: 14686229
Drug: Ganciclovir (oral)
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir (oral)
Trial: 14686229
Drug: CMV immune
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV immune globulin i.v. and oral acyclovir
Trial: 10570746
Drug: Goat IgG
RxNorm normalized name: Goat milk
DrugBank: Goat milk (DB10542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goat IgG antiidiotype vaccine SCV 106 (n = 21)
Trial: 8966142
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of these drugs
Trial: 20495473
Drug: Conditioned placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioned placebo dose reduction condition (50% reduced dose/placebo)
Trial: 20495473
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction only condition (RD)
Trial: 20495473
Drug: No reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No reduction condition (full dose)
Trial: 19086953
Drug: Intensive regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive regimen (80 mg bolus followed by 8 mg/h continuous infusion for 72 h)
Trial: 19086953
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (40 mg bolus daily followed by saline infusion for 72 h)
Trial: 12267108
Drug: Continuation rates
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation rates at 24 months: Cu7 (69), TCu-220C (73), ML Cu250 (74).
Trial: 22336776
Drug: Nitrate 100
RxNorm normalized name: silver nitrate 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate 100 mg
Trial: 22336776
Drug: Nitrate 200
RxNorm normalized name: silver nitrate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate 200 mg
Trial: 22336776
Drug: Nitrate 400
RxNorm normalized name: silver nitrate 400 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate 400 mg
Trial: 22336776
Drug: Nitrate 400
RxNorm normalized name: silver nitrate 400 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate 400 mg plus antibacterial toothpaste
Trial: 22336776
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Nitrate (Control)
Trial: 22336776
Drug: Nitrate doses
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate doses (100 mg, 200 mg, 400 mg)
Trial: 20129511
Drug: Amantadine 4
RxNorm normalized name: amantadine 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days
Trial: 17509511
Drug: Topical 0.02%
RxNorm normalized name: tretinoin topical 0.02% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.02% mitomycin C (MMC) applied for 15 seconds during PRK
Trial: 16284692
Drug: Prophylactic parenteral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic parenteral nutrition (PN)
Trial: 16284692
Drug: PN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN with 0.5 g glutamine/kg as L‐Ala‐L‐Gln
Trial: 7778387
Drug: Glycine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (daily dose 1-2 grams)
Trial: 2316281
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 0.03-3.0 micrograms antigen per dose
Trial: 37045
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate 2 mg
Trial: 37045
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate 4 mg
Trial: 37045
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate 8 mg
Trial: 31190327
Drug: ENR-IV (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENR-IV (10 mg/kg, IV)
Trial: 31190327
Drug: ENR-IM (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENR-IM (10 mg/kg, IM)
Trial: 31190327
Drug: DNX-IV (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNX-IV (8 mg/kg, IV)
Trial: 31190327
Drug: DNX-IM (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNX-IM (8 mg/kg, IM)
Trial: 24148291
Drug: 5% methimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% methimazole ointment applied to the skin around the thyroid and an oral placebo
Trial: 24148291
Drug: Methimazole tablets
RxNorm normalized name: Methimazole Tablets
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole tablets and placebo ointment
Trial: 24148291
Drug: 5% methimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% methimazole ointment
Trial: 24148291
Drug: Methimazole tablets
RxNorm normalized name: Methimazole Tablets
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole tablets
Trial: 21798557
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of 1‐month depot leuprolide acetate (DL)
Trial: 21798557
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg of 3‐month depot leuprolide acetate (DL)
Trial: 21798557
Drug: 22.5 mg
RxNorm normalized name: inositol 22.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 mg of 3‐month depot leuprolide acetate (DL)
Trial: 16867922
Drug: Major depressive
RxNorm normalized name: Rejoyn Digital Therapeutic Software for Major Depressive Disorder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major depressive disorder with concurrent substance use disorder (SUD)
Trial: 16867922
Drug: Major depressive
RxNorm normalized name: Rejoyn Digital Therapeutic Software for Major Depressive Disorder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major depressive disorder without concurrent substance use disorder (SUD)
Trial: 10506597
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with doxorubicin 75 mg/m(2) every 2 weeks for three cycles followed by docetaxel 100 mg/m(2) every 2 weeks for three cycles
Trial: 10506597
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with doxorubicin 56 mg/m(2) plus docetaxel 75 mg/m(2) every 3 weeks for four cycles
Trial: 1671951
Drug: Paracetamol liquid
RxNorm normalized name: RP Scherer Paracetamol Liquid-Filled Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol liquid 10-15 mg/kg every 4 hours as needed for fever
Trial: 28985094
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for first-time dislocation with operative osteochondral fracture requiring excision or repair
Trial: 28985094
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for recurrent instability, favoring medial reconstruction
Trial: 28300867
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg bid
Trial: 24220913
Drug: CRP concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP concentrations ≥ 10.0 mg/L
Trial: 23082602
Drug: Multi-level oral
RxNorm normalized name: Finafta Multi Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-level oral health intervention (home visits by lay health workers, enhancing oral health education and services at health centers, community mobilization)
Trial: 10543733
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of body weight daily
Trial: 10543733
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg daily
Trial: 10543733
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg weekly
Trial: 8559630
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (fourth dose)
Trial: 8559630
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (booster)
Trial: 2378546
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of haloperidol
Trial: 2378546
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of haloperidol
Trial: 2378546
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d of haloperidol
Trial: 31657804
Drug: 14 improvisational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 improvisational music therapy sessions on a weekly basis (Group 1)
Trial: 31657804
Drug: 7 improvisational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 improvisational music therapy sessions alternated with 7 listening music therapy sessions on a weekly basis (Group 2)
Trial: 26395174
Drug: PER/AML 8/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PER/AML 8/10 mg